Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma

Blood. 2018 Jun 21;131(25):2856-2859. doi: 10.1182/blood-2018-03-841262. Epub 2018 May 3.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Cohort Studies
  • Female
  • Hodgkin Disease / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Nivolumab / administration & dosage
  • Nivolumab / therapeutic use*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Remission Induction
  • Young Adult

Substances

  • Antineoplastic Agents, Immunological
  • Programmed Cell Death 1 Receptor
  • Nivolumab